FDA drafts ‘leapfrog’ guidance on brain-computer interface tech

Blue purple pink 3d rendering of brain
The draft guidance details considerations for long-term biocompatibility with blood, cerebrospinal fluid and nerve tissue, as well as electrical and electromagnetic safety standards. (monsitj/iStock/Getty Images Plus)

The FDA is hoping to help the industry take a leap toward what was once pure science fiction: interfaces that link brains and computers, allowing a person to directly control devices with their thoughts.

To promote development of a new generation of fully integrated implants, the agency published a new draft guidance (PDF) that provides the FDA’s initial regulatory considerations as the technology progresses.

The eventual goal is to develop a framework for improving the mobility and independence of patients with paralysis or amputations, including injured veterans, through controllable prostheses.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

In addition, the FDA launched a cross-center working group of 15 internal experts representing different scientific specialties, who will advise the agency on emerging technologies and the FDA’s ability to keep pace in its regulations.

“The FDA is also committed to collaborating with stakeholders, including product developers, across the healthcare ecosystem on specific areas that we know are advancing and ripe for disruption,” Commissioner Scott Gottlieb, M.D., said in an agency statement. “We know innovation is often capital intensive and risky and we understand that we can help reduce the risk and cost of capital to advance these patient opportunities by giving clear direction early in the development process.” 

RELATED: Brain-computer interface allows paralyzed patients to use off-the-shelf tablet

The draft guidance provides recommendations and technical advice for product developers on how to design clinical and nonclinical tests for implanted brain-interface devices, and how nonclinical device testing can demonstrate the mitigation of risks before the launch of a clinical study.

It also details considerations for the long-term biocompatibility with blood, cerebrospinal fluid and nerve tissue, as well as electrical and electromagnetic safety standards, including wireless technology and compatibility with MRI machines.

“The idea that a prosthetic could interact with the brain has been the topic of much imagination, but now we’re actually on the verge of realizing this opportunity,” said Gottlieb.

Suggested Articles

The FDA disclosed over 60 safety reports related to intra-aortic balloon pumps manufactured by Maquet and Datascope, following a recall this summer.

Truvian Sciences raised $27.1 million to fuel the development of its benchtop blood tester, bringing the company’s total funding to $46.3 million.

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.